Table 1.
Prevalence of antibodies in the autism cohort.
| Antigen | Typically developing (N = 55) seropositivity | Developmental delay (N = 25) seropositivity | ASD (N = 103) seropositivitya |
|---|---|---|---|
| GAD-65 | 0/55 | 0/25 | 0/103 |
| Ro52 | 0/55 | 0/25 | 0/103 |
| GFAP | 2/55 | 2/25 | 4/103 |
| AQP-4 | 3/55 | 0/25 | 5/103 |
| TH | 1/55 | 0/25 | 1/103 |
| γ-Enolase | 1/55 | 0/25 | 2/103 |
| XMRV gag | 1/55 | 0/25 | 0/103 |
| MMTV p24 | 1/55 | 0/25 | 0/103 |
a
Fisher exact tests revealed no statistical difference in prevalence of antibodies against the eight targets in ASD compared to typically developing and developmental delay children.